eli lilly retatrutide study Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial Eli Lilly infiltrates anti-obesity market

Shed positions it exactly that way: part of a broader health approach, not a shortcut or a personality transplant

Sex distribution was not analyzed in our study, which is a limitation given evidence that females may be more susceptible to nausea and vomiting induced by GLP-1RAs, potentially due to hormonal influences or differences in gastric emptying rates

Nausea hit me hard during the third week, and I had to cut back on portion sizes dramatically

As of mid-2025, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA)

Warnings Do not exceed recommended dose

SELECT trial cardiovascular data